NWB Bank Selects FINCAD for Portfolio Valuation
FINCAD , the leading provider of integrated analytics for multi-asset portfolio and risk, today announced Nederlandse Waterschapsbank N.V. (NWB) as a new client. A leading financial services provider for the Dutch public sector, NWB selected FINCAD F3 to help consolidate their use of multiple systems for improved valuation consistency and for eliminating the manual data aggregation from the different systems. NWB will also use FINCAD F3 WorkStation , an intuitive and easy-to-use web application for generating and reporting portfolio valuations, risk, and cash flows.
FINCAD will generate consistent valuations on NWB’s portfolio of nearly 7,000 positions consisting of a wide range of instruments from vanilla interest rate swaps to complex structured products, including digital power reverse dual currency notes and callable CMS spreads. FINCAD F3 will enable a reduction in the number of valuation systems, automate and streamline their end of day process, allow better collateral management with counterparties, and improve both internal and regulatory reporting.
“Currently, we have multiple valuation systems valuing different parts of our portfolio, and because each system uses different models, there is a risk of inconsistency and errors,” said Paul Janse, Information Analyst at NWB. “With FINCAD, we will achieve maximum consistency in valuations across our entire portfolio.” Janse added, “We also look forward to the flexibility and transparency of F3, as it allows visibility into all details of the calculations. It’s not a black box.”
In terms of technology, NWB required a solution that could integrate with their treasury system to facilitate accurate end-of-day reporting. FINCAD’s flexibility will enable this, and eliminate the need for the bank to manually aggregate reports from different systems. “Integration with our existing systems is one of our biggest priorities. With FINCAD, we will be able to integrate market data and valuations in an automated and seamless end of day process,” said Janse.
End of day valuations produced by FINCAD will be leveraged for internal reporting, managing balance sheet exposure, and producing external reports required for European Central Bank and Basel III reporting. FINCAD will also be used for the determination of collateral flows between NWB and its swap counterparties, and help the bank better manage counterparty exposure.
“We are pleased to be working with NWB. FINCAD F3 will give the bank access to one integrated solution for generating accurate valuations, helping them to better manage risk and reporting, and to make informed decisions,” commented Bob Park, FINCAD President and CEO. “We have helped many clients such as NWB overcome key valuation and risk challenges such as the need to consolidate the number of valuation systems in use, and the need to move off of error-prone spreadsheets or inflexible home-grown systems. The result for these firms has been improved decision making, reduced operating costs, and the ability to easily enter into new and profitable markets.”
FINCAD is the leading provider of integrated analytics for multi-asset portfolio and risk management. An industry standard since 1990, our advanced analytics, flexible architecture and patented technology enable global financial firms to improve returns, manage risk and comply with regulations. Clients include leading asset managers, hedge funds, insurance companies, pension funds, banks and auditors. For more information, visit www.fincad.com .
Rob Garfield, +1 646-435-5920
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum